TNFAIP6 and metabolic syndrome: MSCs target central pathogenic mechanisms activated by both RAS and MetS, such as inflammation, fibrosis, microvascular loss, and adverse tissue remodeling, by reducing the release of inflammatory cytokines through key vectors, such as the anti-inflammatory protein tumor necrosis factor-stimulated gene-6 (TSG-6) [22].